Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “lung cancer”

Implementation and Effectiveness of the BJC-Pink and Pearl Project on Lung Cancer ScreeningRecruiting
NCT06898333N/AUpdated Aug 12, 2026
Sponsor: Washington University School of Medicine
Lung Cancer · Cancer of the Lung
United States
Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian HospitalRecruiting
NCT07146568NAUpdated Aug 12, 2026
Sponsor: Washington University School of Medicine
Lung Cancer · Cancer of the Lung
United States
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)Active Not Recruiting
NCT04044859Phase 1Updated Aug 12, 2026
Sponsor: USWM CT, LLC
Endometrial Cancer · Esophageal Cancer · Esophagogastric Junction (EGJ) · Gastric (Stomach) Cancer
United States, Canada, Spain
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56Recruiting
NCT04199741Phase 1, Phase 2Updated Aug 12, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Small Cell Lung Cancer · Small Cell Lung Carcinoma
United States
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)Recruiting
NCT05099172Phase 1, Phase 2Updated Aug 12, 2026
Sponsor: Bayer
Advanced Non-small Cell Lung Cancer · EGFR Mutation · HER2 Mutation
United States, Belgium, Brazil, China, France +11 more
A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving PembrolizumabRecruiting
NCT07619599Phase 1Updated Aug 12, 2026
Sponsor: City of Hope Medical Center
Metastatic Lung Non-Small Cell Carcinoma · Metastatic Malignant Neoplasm in the Brain · Oligoprogressive Lung Non-Small Cell Carcinoma · Stage IV Lung Cancer AJCC v8
United States
A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to Increase Lung Cancer Screening Among Black Community Members, RESTORE TrialRecruiting
NCT07490860NAUpdated Aug 12, 2026
Sponsor: Fred Hutchinson Cancer Center
Lung Carcinoma
United States
Lindera Obtusiloba for Non-small Cell Lung CancerCompleted
NCT04348149NAUpdated Aug 12, 2026
Sponsor: Jun-Yong Choi
Non Small Cell Lung Cancer
South Korea
Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung CancerNot Yet Recruiting
NCT07759492Phase 2Updated Aug 12, 2026
Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Non-small Cell Lung Cancer Stage III Unresectable
France
A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLCNot Yet Recruiting
NCT07760519N/AUpdated Aug 12, 2026
Sponsor: AstraZeneca
Carcinoma, Non-Small-Cell Lung
Biodistribution & Pharmacokinetic of Position Emission Tomography (PET) Radiopharmaceutical 18F C SNAT4Suspended
NCT04017819Phase 1Updated Aug 12, 2026
Sponsor: Stanford University
Cancer · Lung Cancer
United States
Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung CancerActive Not Recruiting
NCT03600701Phase 2Updated Aug 11, 2026
Sponsor: National Cancer Institute (NCI)
Metastatic Lung Non-Small Cell Carcinoma · Recurrent Lung Non-Small Cell Carcinoma · Refractory Lung Non-Small Cell Carcinoma · Stage IV Lung Cancer AJCC v8
United States
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerActive Not Recruiting
NCT03392246Phase 2Updated Aug 11, 2026
Sponsor: Dana-Farber Cancer Institute
Non-small Cell Lung Cancer
United States
A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult ParticipantsNot Yet Recruiting
NCT07756645Phase 3Updated Aug 11, 2026
Sponsor: AbbVie
Non-Small Cell Lung Cancer
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid TumorsRecruiting
NCT05706129Phase 1, Phase 2Updated Aug 11, 2026
Sponsor: Lumara Bio Oncologics GmbH
Clear Cell Renal Cell Cancer (ccRCC) · Pancreatic Ductal Adenocarcinoma (PDAC) · Colorectal Cancer (CRC) · Urothelial Carcinoma (UC)
Australia, France
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsRecruiting
NCT05592626Phase 1, Phase 2Updated Aug 11, 2026
Sponsor: Marengo Therapeutics, Inc.
Advanced Solid Tumors · Genital Neoplasm, Female · Urogenital Neoplasms · Lung Neoplasm
United States, Canada, France, Spain
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung CancerActive Not Recruiting
NCT06732401Phase 3Updated Aug 11, 2026
Sponsor: National Cancer Institute (NCI)
Lung Non-Small Cell Carcinoma · Stage II Lung Cancer AJCC v8 · Stage IIIA Lung Cancer AJCC v8 · Stage IIIB Lung Cancer AJCC v8
United States
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid TumorsCompleted
NCT06131398Phase 1Updated Aug 11, 2026
Sponsor: Amgen
Advanced Solid Tumors
United States, Australia, Canada, France, Japan +6 more
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung CancerRecruiting
NCT06656598Phase 2Updated Aug 11, 2026
Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Stage III NSCLC
France
Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural MesotheliomaRecruiting
NCT07234058Phase 2Updated Aug 11, 2026
Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Pleural Mesotheliomas
France
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung CancerCompleted
NCT04085315Phase 1Updated Aug 11, 2026
Sponsor: Collin Blakely
Lung Cancer Metastatic · EGFR Gene Mutation
United States
Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A TrialRecruiting
NCT07382726Phase 1Updated Aug 11, 2026
Sponsor: M.D. Anderson Cancer Center
Non-small Cell Lung Cancer
United States
Continuous Positive Airway Pressure Device or Deep Inspiration Breath Hold in Reducing Tumor Motion in Patients Undergoing Stereotactic Body Radiation Therapy for Lung CancerRecruiting
NCT03422302NAUpdated Aug 11, 2026
Sponsor: M.D. Anderson Cancer Center
Lung Carcinoma · Malignant Respiratory Tract Neoplasm · Metastatic Malignant Neoplasm in the Lung
United States
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutationActive Not Recruiting
NCT04685135Phase 3Updated Aug 11, 2026
Sponsor: Mirati Therapeutics Inc.
Metastatic Non Small Cell Lung Cancer · Advanced Non Small Cell Lung Cancer
United States, Australia, Austria, Belgium, China +19 more
Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung CancerNot Yet Recruiting
NCT07436858Phase 1Updated Aug 11, 2026
Sponsor: The Netherlands Cancer Institute
Lung Cancer (NSCLC) · HER2 Expression · HER2 Gene Mutation
Netherlands

Previous page Next page